Powered by SearchMedica
SearchMedica recommended medical sites    Search ConsultantLive    Prioritize Results by Publication Date

Supplement to Consultant for Pediatricians -- December 2008 Vol 7 No 12


Supported by an educational grant from MedImmune

Respiratory Syncytial Virus: Pathogenesis and Disease Burden

Leonard E. Weisman, MD
Baylor College of Medicine

Respiratory syncytial virus (RSV) is the most important cause of viral lower respiratory tract illness in infants and children worldwide. Each year, it is responsible for over 120,000 hospitalizations of infants in the United States alone. The disease spectrum includes a wide array of upper and lower respiratory tract symptoms that can have a significant impact on morbidity and mortality.

For the full article in PDF form please click here | For a PDF of this month's entire supplement click here

 

 

Respiratory Syncytial Virus: Best Practices for Prevention and Treatment

Dianne S. Charsha, RN, MSN, NNP-BC
Cooper University Hospital

 

A number of methods may be employed to prevent the spread of respiratory syncytial virus (RSV), including simple hand washing, screening of visitors to neonatal ICUs, and appropriate isolation and cohorting of infected infants. These standards of care must also be transferred to the home. Treatments such as acetaminophen, bronchodilators, and the antiviral agent, ribavirin, are available to treat symptoms of infection. Pharmacological prophylaxis with palivizumab and RSV intravenous immunoglobulin may be used in specific at-risk patients.

For the full article in PDF form please click here | For a PDF of this month's entire supplement click here

 
Supplement to Consultant -- November 2008 Vol 48 No 12


Supported by an educational grant from Abbott Laboratories

Striking the Right Balance: The Residual Risk of Coronary Artery Disease
Frank M. Sacks, MD
Harvard School of Public Health

Vera Bittner, MD, MSPH
University of Alabama at Birmingham

David S. Kountz, MD, FACP
Robert Wood Johnson Medical School

Michael Miller, MD, FACC, FAHA
University of Maryland

Elevated low-density lipoprotein cholesterol (LDL-C) is a well-established independent risk factor for coronary artery disease and is the principal lipid target for risk reduction. Statins lower LDL and other apo B–containing lipoproteins, thereby leading to a 20% to 35% reduction in major cardiovascular events, but do not comprehensively address the multiple lipid abnormalities of atherogenic dyslipidemia

For the full article in PDF form please click here
Supplement to Consultant For Pediatricians -- September 2008 Vol 7 No 9


Special Issue: Focus on Vaccines Supplement
For a PDF of this month's entire supplement click here


Supplement to Consultant -- September 2008 Vol 48 No 10


Supported by Boehringer Ingelheim Pharmaceuticals

Parkinson Disease in Primary Practice: Keys to Diagnosis and Management
H. James Brownlee, MD
University of South Florida College of Medicine

More than 1 million Americans older than 60 years have Parkinson disease (PD). Diagnosis is clinical and based on the history and physical findings. The 4 cardinal motor symptoms are bradykinesia, resting tremor, muscle rigidity, and a gait disorder. The stereotypic PD tremor is a "pill-rolling" movement of the fingers and thumb with the arm at rest in the lap.

For the full article in PDF form please click here | For a PDF of this month's entire supplement click here

Dopamine Agonists in Parkinson Disease: Special Focus on Pramipexole
Theresa A. Zesiewicz, MD, FAAN
University of South Florida College of Medicine

Dopamine receptor agonists have played an important role in antiparkinsonian therapy since the first ergoline derivative was introduced in 1974. The non-ergoline dopamine agonists, developed later to provide the benefits of the ergolines with fewer side effects, are currently used as both monotherapy and as adjunctive therapy to treat symptoms of Parkinson disease (PD), to postpone the onset of levodopa therapy, to delay the development and minimize the severity of levodopa’s complications, and to reduce the dosage of levodopa.

For the full article in PDF form please click here | For a PDF of this month's entire supplement click here